---
document_datetime: 2025-11-23 08:07:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ordspono.html
document_name: ordspono.html
version: success
processing_time: 0.1079622
conversion_datetime: 2025-12-28 09:49:14.410099
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ordspono

[RSS](/en/individual-human-medicine.xml/244582)

##### Authorised

This medicine is authorised for use in the European Union

odronextamab

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ordspono](#news-on)
- [More information on Ordspono](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ordspono is a cancer medicine for treating adults with follicular lymphoma or diffuse large B-cell lymphoma (DLBCL), two types of blood cancer. Ordspono is used when the cancer has returned (relapsed) or not responded (refractory) after at least two previous therapies that affect the whole body (systemic therapies).

Ordspono contains the active substance odronextamab.

Expand section

Collapse section

## How is Ordspono used?

Ordspono can only be obtained with a prescription, and treatment must be monitored by a healthcare professional experienced in the treatment of cancer. It should be given in a setting with appropriate medical support to manage severe reactions due to cytokine release syndrome (a potentially life-threatening condition that causes fever, vomiting, shortness of breath, headache and low blood pressure).

Ordspono is given as an infusion (drip) into a vein. Treatment starts with four 21-day cycles. In the first cycle, infusions are given on days 1, 2, 8, 9, 15 and 16 at increasing doses; in cycles 2 to 4, infusions are given on days 1, 8 and 15. Ordspono is then given every 2 or 4 weeks, depending on how the patient responds to treatment. Treatment should continue until the disease gets worse or the patient experiences unacceptable side effects.

To reduce the risk of developing cytokine release syndrome and infusion-related reactions, patients are given medicines before and after certain Ordspono infusions for the first 2 cycles, and beyond if needed.

The doctor may delay doses if certain side effects occur or stop treatment altogether for certain severe side effects.

For more information about using Ordspono, see the package leaflet or contact your doctor or pharmacist.

## How does Ordspono work?

Follicular lymphoma and DLBCL are cancers that affect B cells, a type of white blood cell. The active substance in Ordspono, odronextamab, is an antibody (a type of protein) which is described as 'bispecific' because it recognises and attaches to two targets simultaneously: CD20, a protein on the surface of B cells (including the cancer cells), and CD3, a protein on the surface of T cells (cells of the immune system). By attaching to CD20 and CD3 proteins, Ordspono brings the cancer cells and T cells together. This activates the T cells which then kill the cancer cells, helping to control the disease.

## What benefits of Ordspono have been shown in studies?

Ordspono was tested in a main study involving patients with different types of lymphoma, including 128 patients with follicular lymphoma and 127 patients with DLBCL, whose cancer had returned or not responded after at least two previous treatments. Ordspono was not compared with any other treatment.

The study showed that around 80% of patients with follicular lymphoma had a response to treatment: about 73% (94 out of 128) had a complete response (no signs of cancer) and 7% (9 out of 128) had a partial response after 52 weeks of treatment. The responses were maintained for an average of 23 months. Of the patients with DLBCL about 52% responded to treatment: about 31% (40 out of 127) had a complete response and 20% (26 out of 127) had a partial response after 36 weeks of treatment. The responses were maintained for 11 months on average.

## What are the risks associated with Ordspono?

For the full list of side effects and restrictions with Ordspono, see the package leaflet.

The most common side effects with Ordspono (which may affect more than 1 in 5 people) include cytokine release syndrome, neutropenia ((low levels of neutrophils, a type of white blood cell that fights infection), fever, anaemia (low levels of red blood cells), thrombocytopenia (low levels of blood platelets), diarrhoea and COVID-19.

The most common serious side effects include cytokine release syndrome (which may affect more than 1 in 10 people), as well as pneumonia (lung infection), COVID-19 and fever, which may affect up to 1 in 10 people.

## Why is Ordspono authorised in the EU?

At the time of approval, there were limited treatment options for patients with follicular lymphoma or DLBCL whose cancer had returned or not responded after at least two systemic therapies. In studies most patients had a response to treatment, which was either complete or partial. Although the medicine was not compared with other treatments, these results are considered highly relevant for these patients. In terms of safety, the side effects with Ordspono are similar to those seen with other medicines of the same class. Although serious side effects can occur, measures will be in place to help manage these risks. The European Medicines Agency therefore decided that Ordspono's benefits are greater than its risks and it can be authorised for use in the EU.

Ordspono has been given conditional authorisation. This means that it has been authorised on the basis of less comprehensive data than are normally required because it fulfils an unmet medical need. The Agency considers that the benefit of having the medicine available earlier outweighs any risks associated with using it while awaiting further evidence.

The company must provide further data on Ordspono. It must submit data on the effectiveness and safety of the medicine in patients with relapsed or refractory follicular lymphoma or DLBCL compared with that of other therapies for treating these cancers. Every year, the Agency will review any new information that becomes available.

## What measures are being taken to ensure the safe and effective use of Ordspono?

The company that markets Ordspono will provide an alert card to patients receiving the medicine with important information on the risk of cytokine release syndrome and neurological toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS, a neurological disorder with symptoms that include problems with speech and writing, confusion and altered consciousness). The card will include instructions on when to seek urgent attention from a healthcare provider or seek emergency help.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ordspono have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ordspono are continuously monitored. Suspected side effects reported with Ordspono are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ordspono

Ordspono received a conditional marketing authorisation valid throughout the EU on 22 August 2024.

Ordspono : EPAR - Medicine overview

Reference Number: EMA/313527/2024

English (EN) (126.01 KB - PDF)

**First published:** 19/11/2024

[View](/en/documents/overview/ordspono-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-154)

български (BG) (149.36 KB - PDF)

**First published:**

19/11/2024

[View](/bg/documents/overview/ordspono-epar-medicine-overview_bg.pdf)

español (ES) (125.51 KB - PDF)

**First published:**

19/11/2024

[View](/es/documents/overview/ordspono-epar-medicine-overview_es.pdf)

čeština (CS) (150.54 KB - PDF)

**First published:**

19/11/2024

[View](/cs/documents/overview/ordspono-epar-medicine-overview_cs.pdf)

dansk (DA) (152.85 KB - PDF)

**First published:**

19/11/2024

[View](/da/documents/overview/ordspono-epar-medicine-overview_da.pdf)

Deutsch (DE) (128.6 KB - PDF)

**First published:**

19/11/2024

[View](/de/documents/overview/ordspono-epar-medicine-overview_de.pdf)

eesti keel (ET) (124.13 KB - PDF)

**First published:**

19/11/2024

[View](/et/documents/overview/ordspono-epar-medicine-overview_et.pdf)

ελληνικά (EL) (148.99 KB - PDF)

**First published:**

19/11/2024

[View](/el/documents/overview/ordspono-epar-medicine-overview_el.pdf)

français (FR) (127.07 KB - PDF)

**First published:**

19/11/2024

[View](/fr/documents/overview/ordspono-epar-medicine-overview_fr.pdf)

hrvatski (HR) (150.72 KB - PDF)

**First published:**

19/11/2024

[View](/hr/documents/overview/ordspono-epar-medicine-overview_hr.pdf)

italiano (IT) (124.38 KB - PDF)

**First published:**

19/11/2024

[View](/it/documents/overview/ordspono-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (157.53 KB - PDF)

**First published:**

19/11/2024

[View](/lv/documents/overview/ordspono-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (148.28 KB - PDF)

**First published:**

19/11/2024

[View](/lt/documents/overview/ordspono-epar-medicine-overview_lt.pdf)

magyar (HU) (150.03 KB - PDF)

**First published:**

19/11/2024

[View](/hu/documents/overview/ordspono-epar-medicine-overview_hu.pdf)

Malti (MT) (151.77 KB - PDF)

**First published:**

19/11/2024

[View](/mt/documents/overview/ordspono-epar-medicine-overview_mt.pdf)

Nederlands (NL) (124.31 KB - PDF)

**First published:**

19/11/2024

[View](/nl/documents/overview/ordspono-epar-medicine-overview_nl.pdf)

polski (PL) (151.14 KB - PDF)

**First published:**

19/11/2024

[View](/pl/documents/overview/ordspono-epar-medicine-overview_pl.pdf)

português (PT) (125.72 KB - PDF)

**First published:**

19/11/2024

[View](/pt/documents/overview/ordspono-epar-medicine-overview_pt.pdf)

română (RO) (146.14 KB - PDF)

**First published:**

19/11/2024

[View](/ro/documents/overview/ordspono-epar-medicine-overview_ro.pdf)

slovenčina (SK) (149.78 KB - PDF)

**First published:**

19/11/2024

[View](/sk/documents/overview/ordspono-epar-medicine-overview_sk.pdf)

slovenščina (SL) (147.25 KB - PDF)

**First published:**

19/11/2024

[View](/sl/documents/overview/ordspono-epar-medicine-overview_sl.pdf)

Suomi (FI) (122.99 KB - PDF)

**First published:**

19/11/2024

[View](/fi/documents/overview/ordspono-epar-medicine-overview_fi.pdf)

svenska (SV) (123.8 KB - PDF)

**First published:**

19/11/2024

[View](/sv/documents/overview/ordspono-epar-medicine-overview_sv.pdf)

Ordspono : EPAR - Risk management plan

English (EN) (506.82 KB - PDF)

**First published:** 19/11/2024

[View](/en/documents/rmp/ordspono-epar-risk-management-plan_en.pdf)

## Product information

Ordspono : EPAR - Product information

English (EN) (666.34 KB - PDF)

**First published:** 19/11/2024

**Last updated:** 19/09/2025

[View](/en/documents/product-information/ordspono-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-20)

български (BG) (642.62 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/bg/documents/product-information/ordspono-epar-product-information_bg.pdf)

español (ES) (594.8 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/es/documents/product-information/ordspono-epar-product-information_es.pdf)

čeština (CS) (572.92 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/cs/documents/product-information/ordspono-epar-product-information_cs.pdf)

dansk (DA) (572.22 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/da/documents/product-information/ordspono-epar-product-information_da.pdf)

Deutsch (DE) (579 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/de/documents/product-information/ordspono-epar-product-information_de.pdf)

eesti keel (ET) (571.24 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/et/documents/product-information/ordspono-epar-product-information_et.pdf)

ελληνικά (EL) (613.94 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/el/documents/product-information/ordspono-epar-product-information_el.pdf)

français (FR) (587.42 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/fr/documents/product-information/ordspono-epar-product-information_fr.pdf)

hrvatski (HR) (610.76 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/hr/documents/product-information/ordspono-epar-product-information_hr.pdf)

íslenska (IS) (514.71 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/is/documents/product-information/ordspono-epar-product-information_is.pdf)

italiano (IT) (482.31 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/it/documents/product-information/ordspono-epar-product-information_it.pdf)

latviešu valoda (LV) (578.75 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/lv/documents/product-information/ordspono-epar-product-information_lv.pdf)

lietuvių kalba (LT) (621.24 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/lt/documents/product-information/ordspono-epar-product-information_lt.pdf)

magyar (HU) (643.77 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/hu/documents/product-information/ordspono-epar-product-information_hu.pdf)

Malti (MT) (634.66 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/mt/documents/product-information/ordspono-epar-product-information_mt.pdf)

Nederlands (NL) (584.39 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/nl/documents/product-information/ordspono-epar-product-information_nl.pdf)

norsk (NO) (519.16 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/no/documents/product-information/ordspono-epar-product-information_no.pdf)

polski (PL) (616.77 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/pl/documents/product-information/ordspono-epar-product-information_pl.pdf)

português (PT) (557.22 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/pt/documents/product-information/ordspono-epar-product-information_pt.pdf)

română (RO) (580 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/ro/documents/product-information/ordspono-epar-product-information_ro.pdf)

slovenčina (SK) (661.92 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/sk/documents/product-information/ordspono-epar-product-information_sk.pdf)

slovenščina (SL) (621.41 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/sl/documents/product-information/ordspono-epar-product-information_sl.pdf)

Suomi (FI) (554.13 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/fi/documents/product-information/ordspono-epar-product-information_fi.pdf)

svenska (SV) (573.35 KB - PDF)

**First published:**

19/11/2024

**Last updated:**

19/09/2025

[View](/sv/documents/product-information/ordspono-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000254850 23/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ordspono : EPAR - All authorised presentations

English (EN) (42.77 KB - PDF)

**First published:** 19/11/2024

[View](/en/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-212)

български (BG) (75.73 KB - PDF)

**First published:**

19/11/2024

[View](/bg/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_bg.pdf)

español (ES) (69.74 KB - PDF)

**First published:**

19/11/2024

[View](/es/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_es.pdf)

čeština (CS) (72.26 KB - PDF)

**First published:**

19/11/2024

[View](/cs/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (72.23 KB - PDF)

**First published:**

19/11/2024

[View](/da/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (72.59 KB - PDF)

**First published:**

19/11/2024

[View](/de/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (67.93 KB - PDF)

**First published:**

19/11/2024

[View](/et/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (72.08 KB - PDF)

**First published:**

19/11/2024

[View](/el/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_el.pdf)

français (FR) (68.96 KB - PDF)

**First published:**

19/11/2024

[View](/fr/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (69.96 KB - PDF)

**First published:**

19/11/2024

[View](/hr/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (71.43 KB - PDF)

**First published:**

19/11/2024

[View](/is/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_is.pdf)

italiano (IT) (69.02 KB - PDF)

**First published:**

19/11/2024

[View](/it/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (71.78 KB - PDF)

**First published:**

19/11/2024

[View](/lv/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (70.87 KB - PDF)

**First published:**

19/11/2024

[View](/lt/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (71.33 KB - PDF)

**First published:**

19/11/2024

[View](/hu/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (71.52 KB - PDF)

**First published:**

19/11/2024

[View](/mt/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (68.43 KB - PDF)

**First published:**

19/11/2024

[View](/nl/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (72.21 KB - PDF)

**First published:**

19/11/2024

[View](/no/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_no.pdf)

polski (PL) (71.78 KB - PDF)

**First published:**

19/11/2024

[View](/pl/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_pl.pdf)

português (PT) (70.98 KB - PDF)

**First published:**

19/11/2024

[View](/pt/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_pt.pdf)

română (RO) (69.9 KB - PDF)

**First published:**

19/11/2024

[View](/ro/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (72.37 KB - PDF)

**First published:**

19/11/2024

[View](/sk/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (69.85 KB - PDF)

**First published:**

19/11/2024

[View](/sl/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (67.95 KB - PDF)

**First published:**

19/11/2024

[View](/fi/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (70.12 KB - PDF)

**First published:**

19/11/2024

[View](/sv/documents/all-authorised-presentations/ordspono-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ordspono Active substance odronextamab International non-proprietary name (INN) or common name odronextamab Therapeutic area (MeSH) Lymphoma, Follicular Anatomical therapeutic chemical (ATC) code Not yet assigned

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy.

Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.

## Authorisation details

EMA product number EMEA/H/C/006215

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Regeneron Ireland Designated Activity Company (DAC)

One Warrington Place Dublin 2 D02 HH27 Ireland

Opinion adopted 27/06/2024 Marketing authorisation issued 22/08/2024 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ordspono : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.33 KB - PDF)

**First published:** 19/09/2025

[View](/en/documents/procedural-steps-after/ordspono-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Ordspono : Orphan designation withdrawal assessment report (initial authorisation)

Reference Number: EMA/OD/0000168564

English (EN) (913.79 KB - PDF)

**First published:** 19/11/2024

[View](/en/documents/orphan-maintenance-report/ordspono-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Ordspono : EPAR - Public assessment report

Adopted

Reference Number: EMA/518269/2024

English (EN) (6.97 MB - PDF)

**First published:** 19/11/2024

[View](/en/documents/assessment-report/ordspono-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ordspono

Adopted

Reference Number: EMA/CHMP/276689/2024

English (EN) (155.74 KB - PDF)

**First published:** 28/06/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ordspono_en.pdf)

#### News on Ordspono

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024) 28/06/2024

#### More information on Ordspono

- [EU/3/22/2656 - orphan designation for treatment of diffuse large B-cell lymphoma](/en/medicines/human/orphan-designations/eu-3-22-2656)
- [EU/3/22/2649 - orphan designation for treatment of follicular lymphoma](/en/medicines/human/orphan-designations/eu-3-22-2649)

**This page was last updated on** 19/09/2025

## Share this page

[Back to top](#main-content)